Ibio Inc Stock News

- IBIO-201, a subunit vaccine combining SARS-CoV-2 spike protein antigens with the Company’s proprietary LicKM booster technology, advances to preclinical immunization studies.

Don't bet the ranch, but consider these five high-risk micro-cap stocks a buy, as each one has the potential for big gains.

If iBio (NYSEMKT:IBIO) gets U.S. Food and Drug Administration approval for its plant-based vaccine for the novel coronavirus, the stock could soar. IBIO stock presently has a $190 million market capit

A race to develop a coronavirus vaccine is on, and these red-hot Covid-19 vaccine stocks are leading the way on that front.

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of Ma

The novel coronavirus pandemic has wreaked havoc on markets, and just when stocks are into recovery mode, we have the specter of a recession to reckon with. If not an outright depression. That's going

We're starting to see a little light at the end of the coronavirus tunnel. State economies are slowly reopening and the market has recovered mightily from March's historic losses.It's true that as we

Certain industries aren’t just growing despite the coronavirus pandemic, they’re growing because of it.

Gainers Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) shares climbed 69.4% to close at $19.50 on Tuesday after the company presented positive preclinical and initial clinical data...

iBio, Inc. (NYSE: IBIO) shares are trading higher after the company provided an update on its COVID-19 vaccine manufacturing capacity. The company estimates it can make roughly 500 million doses of CO